Yamashita Mami, Takenaka Hideomi Yamashita Ryousuke, Nakagawa Keiichi
Hepatogastroenterology. 2014 Oct;61(135):1971-8.
Outcomes were examined for the cases that received radiotherapy (RT) for esophageal cancer with metastasis to supraclavicular lymph nodes (ScLN) in a single institutional retrospective study.
Cases examined were 53 consecutive patients with pathologically confirmed esophageal cancer enrolled from our institution who received semi-radical RT from 2001 to 2013. Radiotherapy consisted of a total dose of from 50-50.4 Gy given in 25-28 fractions of 1.8-2.0 Gy with five fractions per week. The chemotherapy regimen included nedaplatin and 5-fluorouracil. All had ScLN metastasis, and all diseases were included in the RT field.
The median follow up time was 42 months for survival patients. Overall survival (OS) and progression free survival (PFS) for 1-, 2-, and 3 years were 39%, 19%, and 12% and 14%, 9%, and 6%, respectively. Acute grade 3-5 esophagitis and neutropenia was seen in 11% and 81%, respectively. Late grade 3-5 toxicity in esophagus, lung, and heart was seen in 4%, 0%, and 0%. Five patients (9%) survived more than 4 year.
Although the 2-year PFS was less than 10% and very poor, long term survival for over 4 year was seen in 9% cases. In other words, despite the poor results, the fact remains that some patients were cured with CRT.
在一项单机构回顾性研究中,对锁骨上淋巴结转移的食管癌接受放射治疗(RT)的病例的结局进行了检查。
所检查的病例为2001年至2013年期间从本机构招募的53例经病理确诊的食管癌患者,他们接受了半根治性放疗。放疗总剂量为50 - 50.4 Gy,分25 - 28次给予,每次1.8 - 2.0 Gy,每周5次。化疗方案包括奈达铂和5-氟尿嘧啶。所有患者均有锁骨上淋巴结转移,且所有病变均纳入放疗野。
存活患者的中位随访时间为42个月。1年、2年和3年的总生存期(OS)分别为39%、19%和12%,无进展生存期(PFS)分别为14%、9%和6%。急性3 - 5级食管炎和中性粒细胞减少症的发生率分别为11%和81%。食管、肺和心脏的晚期3 - 5级毒性反应发生率分别为4%、0%和0%。5例患者(9%)存活超过4年。
尽管2年PFS小于10%且非常差,但9%的病例出现了超过4年的长期生存。换句话说,尽管结果不佳,但仍有一些患者通过放化疗治愈。